The buyout will also help Pfizer tap into the growing market for biosimilars, which are cheaper versions of biologic drugs that are used to treat conditions such as anemia.
Shares of both companies rose in morning trading today. Hospira Inc., based in Lake Forest, Illinois, is a provider of injectable drugs and infusion technologies. It also offers biosimilars.
Hospira announced last month that it was seeking approval from the Food and Drug Administration for Retacrit, a proposed biosimilar to the anemia treatments Epogen from Amgen and Procrit from Janssen.
Pfizer which is the world's second-largest drugmaker by revenue said that it will use its global network to help expand Hospira's reach to Europe and key emerging markets.
Also Read
Hospira's products are currently distributed mostly in the US Pfizer, a Dow component whose products include Viagra and painkiller Celebrex, has been under pressure from investors to boost its share price.
The company has sold and spun off big parts of its business over the last few years, including animal health, nutrition and a capsule-making unit. This has helped, but hasn't satisfied detractors.